Mary Moffett Barker

Although the acute phase of the COVID-19 pandemic is behind us, Post COVID-19 Condition (PCC) remains a significant challenge for post-pandemic society. PCC is a serious and often debilitating condition affecting an as-yet undetermined proportion of individuals infected with SARS-CoV-2. In the absence of validated treatments, PCC poses substantial challenges to the health, functioning, and quality of life of affected individuals, and, consequently, to labor markets and national economies. The overarching aim of this project is to use unique register-, cohort-, and biobank data in Sweden, Iceland, Denmark, Norway and Estonia, to assess the prevalence and health and ecnomic impacts of PCC. We will first assess the prevalence of PCC in these five countries, using two new screening methods. We will then study health trajectories following PCC and identify potential genetic and metabolic biomarkers for such trajectories. Finally, we will analyze the personal and societal costs associated with PCC, including changes in earnings and disposable income, healthcare use, and loss of productivity (e.g., sick leave and disability pension). The combination of large-scale data sources, cutting-edge analytical approaches, cross-country comparisons, and a highly experienced research team jointly underscores the scientific novelty and significance of this project. Findings from this project are meant to importantly contribute to a better preparedness of our society for future pandemics.